Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 50 to 59 ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

while adults 60 or older with an underlying health condition should ask about their RSV vaccination options. The vaccine for this population is usually AREXVY. Receiving your vaccine doesn’t only help ...

Health Canada has approved the vaccine, mRESVIA, for the prevention of lower respiratory tract disease in older adults, the company said.

In June, the FDA expanded the approval of GSK's RSV vaccine (Arexvy) to include adults ages 50-59 at increased risk of lower ...